ProfileGDS4814 / ILMN_1680860
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 88% 87% 87% 89% 87% 87% 87% 88% 89% 89% 88% 90% 88% 86% 89% 87% 87% 87% 88% 88% 89% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)327.11888
GSM780708Untreated after 4 days (C2_1)294.42987
GSM780709Untreated after 4 days (C3_1)274.80287
GSM780719Untreated after 4 days (C1_2)366.7889
GSM780720Untreated after 4 days (C2_2)298.58387
GSM780721Untreated after 4 days (C3_2)282.20287
GSM780710Trastuzumab treated after 4 days (T1_1)290.31787
GSM780711Trastuzumab treated after 4 days (T2_1)339.5988
GSM780712Trastuzumab treated after 4 days (T3_1)368.42189
GSM780722Trastuzumab treated after 4 days (T1_2)342.40689
GSM780723Trastuzumab treated after 4 days (T2_2)327.04988
GSM780724Trastuzumab treated after 4 days (T3_2)392.54690
GSM780713Pertuzumab treated after 4 days (P1_1)327.35288
GSM780714Pertuzumab treated after 4 days (P2_1)243.97286
GSM780715Pertuzumab treated after 4 days (P3_1)354.04589
GSM780725Pertuzumab treated after 4 days (P1_2)289.0187
GSM780726Pertuzumab treated after 4 days (P2_2)277.96987
GSM780727Pertuzumab treated after 4 days (P3_2)284.00687
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)331.90888
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)328.80888
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)360.55289
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)325.60488
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)322.79588